MeiraGTx Holdings plc
MGTX$525M
Small CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaNEW YORK
Drugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 13, 2026
7wMarket Overview
Stock performance and key metrics
MGTX News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
adeno-associated virus vector AAV- CNGA3
Achromatopsia
AAV - CNGB3
Achromatopsia
AAV RPE65
Leber Congenital Amaurosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
adeno-associated virus vector AAV- CNGA3 | Phase 2 | Achromatopsia | - | - |
AAV - CNGB3 | Phase 2 | Achromatopsia | - | - |
AAV RPE65 | Phase 2 | Leber Congenital Amaurosis | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply